Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

March 14, 2013

Las Vegas, Nevada

Scientific Agenda

Thursday, March 14, 2013

Moderator: Morton Coleman, MD

3:00 pm

Welcome and Introductions

3:05 pm

Pre-activity knowledge/competence polling via ARRAY Technology

3:10 pm

AML and MDS
William G. Blum, MD

  • Risk stratification and treatment decisions in AML
  • Novel treatment strategies for AML
  • low and intermediate-1 risk MDS
  • Intermediate-2 and high risk MDS

3:35 pm

3:35 pm Q&A Session including post-activity knowledge/competence polling via ARRAY Technology

3:40 pm

Myeloproliferative Neoplasms and Chronic Myeloid Leukemia
Michael Mauro, MD

  • Molecular biology of MPNs
  • JAK2 inhibitors
  • Beyond JAK2 inhibitors
  • Selecting appropriate frontline therapy for CML
  • Managing long term TKI therapy in CML
  • T315I and other “resistant” mutations in CML

4:05 pm

Q&A Session including post-activity knowledge/competence polling via ARRAY Technology

4:10 pm

Chronic Lymphocytic Leukemia
Kanti R. Rai, MD

  • FCR and BR and Len-R
  • Novel agents and their role in frontline and relapsed CLL
  • Who should be referred for allogeneic SCT?

4:35 pm

Q&A Session including post-activity knowledge/competence polling via ARRAY Technology

4:40 pm

Aggressive Non-Hodgkins Lymphomas and Hodgkins Lymphoma
Morton Coleman, MD

  • Therapeutic Options for Early Stage Diffuse Large B-Cell Lymphoma
  • Advanced Stage DLBCL
  • Molecular Markers and Novel Targets for DLBC Lymphoma
  • Emerging Therapies for DLBC Lymphoma
  • Improving the Risk/Benefit Ratio for HL
  • Novel Therapies for Relapsed HL
  • The Role for Radiotherapy in HL

5:05 pm

Q&A Session including post-activity knowledge/competence polling via ARRAY Technology

5:10 pm

Coffee Break

5:30 pm

Indolent Lymphomas, Mantle Cell Lymphomas & T-Cell Lymphomas
Myron Czuczman, MD

  • Frontline Therapy for Follicular Lymphomas
  • Novel Therapies for Advanced Follicular Lymphomas
  • Maintenance Therapies for Indolent Lymphomas
  • The Role of PI3K and BTK inhibitors
  • Frontline Therapy for Mantle Cell Lymphoma
  • Novel Therapies for MCL
  • Advances in T-cell lymphoma therapy

5:50 pm

Q&A Session including post-activity knowledge/competence polling via ARRAY Technology

5:55 pm

Frontline Therapy and Maintenance for Newly Diagnosed Multiple Myeloma
Leif Bergsagel, MD

  • Transplant eligible versus transplant ineligible patients
  • Doublets versus Triplets
  • Integrating Novel Agents into Frontline Regimens
  • Proteasome inhibitors and immunomodulatory agents
  • Duration of maintenance

6:15 pm

Advances in the Management of Relapsed/Refractory Multiple Myeloma
Keith Stewart, MD

  • Novel Proteasome Inhibitors
  • Novel Immunomodulatory Drugs
  • Monoclonal Antibodies for Myeloma
  • HDAC Inhibitors
  • HSP90, PI3K and Akt inhibitors
  • Kinesin Spindle Protein inhibitors

6:35 pm

Q&A Session including post-activity knowledge/competence polling via ARRAY Technology

6:40 pm

Panel Discussion with the Faculty: Survivorship Issues in Hematologic Malignancies
Moderator: Morton Coleman, MD

7:00 pm

Adjourn